Table 2 In vivo efficiency against human SW620 colon cancer in nude mice

From: Tumor regression achieved by encapsulating a moderately soluble drug into a polymeric thermogel

   

Animal number

  

Group

Drug dose (mg/kg/w)

Delivery Route

Start

End

Tumor weight (g)

Tumor inhibition ratio (%)e)

NSa)

0

s.c.

6

6

1.82 ± 0.45

 

Thermogelb)

0

s.c.

6

6

2.21 ± 0.49

/

IRNc)

22.5

i.v.

6

6

0.87 ± 0.27

52.3

IRNc)

45

i.v.

6

6

0.55 ± 0.21

69.9

IRNc)

90

i.v.

6

6

0.36 ± 0.12

80.5

IRN/thermogeld)

22.5

s.c.

6

6

0.25 ± 0.47

86.2

IRN/thermogeld)

45

s.c.

6

6

0.05 ± 0.01

97.5

IRN/thermogeld)

90

s.c.

6

6

0.03 ± 0.01

98.2

  1. a)NS: normal saline as the negative control.
  2. b)Thermogel: polymer solutions only with 20 wt% PLGA-PEG-PLGA. A 0.45 mL polymer solution was injected subcutaneously into the back of each mouse on days 0, 7 and 14, with tumor tissues inoculated in the right armpit.
  3. c)IRN: drug solution only (1 mg/mL, 2 mg/mL, or 4 mg/mL) in normal saline. A 0.45 mL drug solution was injected intravenously into each mouse on days 0, 7 and 14.
  4. d)IRN/thermogel: IRN (1 mg/mL, 2 mg/mL, or 4 mg/mL) in polymer solutions (20 wt% PLGA-PEG-PLGA). A 0.45 mL mixture solution of the drug and polymer was injected subcutaneously into the back of each mouse on days 0, 7 and 14.
  5. e)Calculated from equation (2). A tumor inhibition value >40% indicates effectiveness.
Back to article page